Sulf2
Catalog number: X1853B| Product Type |
Blocking Peptide |
| Units | 50 µg |
| Application |
Functional Inhibition |
Background
Sulf-2 exhibits arylsulfatase activity and highly specific endoglucosamine-6-sulfatase activity. It can remove sulfate from the C-6 position of glucosamine within specific subregions of intact heparin. Heparan sulfate proteoglycans act as co-receptors for numerous heparin- binding growth factors and cytokines and are key regulators of cell signaling. Growth factor binding to heparan sulfate results in mitogenic activity only when specific structural features are present within the heparan sulfate chains. These features include sulfation at specific positions within a disaccharide (N, 2-O, 3-O, 6-O) by the enzymes that regulate heparan sulfate synthesis inside the Golgi. Following synthesis and expression, heparan sulfate can be structurally and functionally modified within the extracellular compartment. Enzymes known to have these effects are heparanase, which cleaves heparan sulfate chains into smaller biologically active fragments, and the heparan sulfate 6-O-endosulfatases (Sulfs). The Sulfs represent a new and novel family of enzymes that are secreted via the Golgi and subsequently localized to the cell surface or may be released into the extracellular matrix. Sulf-1 enzyme is required for Wnt-mediated signaling in developing quail muscle. Sulf1 was shown (in quial) to restore bone morphogenetic protein signaling in cells by releasing the functional inhibitor, Noggin, from cell surfaces. Quail Sulf1 can also inhibit growth factor signaling, the removal of the 6-O-sulfation is required for the formation of the FGF HS FR1c ternary complex blocking FGF2 signaling. Analysis of human tumor tissue and tumor cell lines suggests that HSulf-1 is misregulated in cancers. HSulf-1 is found in a variety of normal tissues but is down-regulated in tumor cell lines originating from ovarian, breast, pancreatic, renal, and hepatocellular carcinoma. Tumors formed by cells expressing Sulf demonstrate enhanced extracellular matrix deposition. The 6-O-sulfation of heparan sulfate of myeloma tumor cells may be a critical factor in determiningand regulating the in vivo growth of this cancer.
Synonyms: Extracellular Sulfatase-2, HSulf-2
Product
Product Form: Unconjugated
Formulation: Provided as solution in phosphate buffered saline with 0.08% sodium azide
Concentration: See vial for concentration
Applications
Blocking peptide for use with Sulf-2 antibodies (Cat. Nos. X1858P & X1865P).
Functional Analysis: Antibody Function Blocking
Storage
Product should be stored at -20°C. Aliquot to avoid freeze/thaw cycles
Product Stability: See expiration date on vial
Shipping Conditions: Ship at ambient temperature, freeze upon arrival
Caution
This product is intended FOR RESEARCH USE ONLY, and FOR TESTS IN VITRO, not for use in diagnostic or therapeutic procedures involving humans or animals. It may contain hazardous ingredients. Please refer to the Safety Data Sheets (SDS) for additional information and proper handling procedures. Dispose product remainders according to local regulations.This datasheet is as accurate as reasonably achievable, but Nordic-MUbio accepts no liability for any inaccuracies or omissions in this information.
Protein Reference(s)
Database Name: UniProt
Accession Number: Q8IWU5
Species Accession: Human
Safety Datasheet(s) for this product:
| NM_Sodium Azide |